Int J Stomatol

Inter J Stomatol ›› 2017, Vol. 44 ›› Issue (5): 596-601.doi: 10.7518/gjkq.2017.05.021

• Reviews • Previous Articles     Next Articles

Correlation between Toll-like receptor 9 and head and neck squamous cell carcinoma

Zhang Xu, Xu Enxin, Ruan Min.   

  1. Dept. of Oral and Maxillofacial-Head and Neck Oncology, Ninth People’s Hospital, Shanghai JiaoTong University School of Medicine;Shanghai Key Laboratory of Stomatology & Shanghai Research Institute of Stomatology;National Clinical Research Center of Stomatology, Shanghai 200011, China
  • Received:2016-12-13 Revised:2017-06-10 Online:2017-09-01 Published:2017-09-01
  • Supported by:

    ; This study was supported by National Natural Science Foundation of China(81102049, 81472517) and Shanghai Pujiang Program(15PJD024).

RichHTML

5

PDF (PC)

198

Abstract:

Chronic inflammation has close relation with the occurrence and development of malignant neoplasms, including head and neck squamous cell carcinoma(HNSCC). Toll-like receptor(TLR) may play an important role in this process. Toll-like receptor is a kind of the pattern recognition receptors which mediates the innate immune response by recognizing the pathogen-associated molecular pattern. High expression of TLR9 is found in some malignant neoplasms, including HNSCC, and has the ability to promote the proliferation, invasion and metastasis of tumor cells. As one of the key factors in the control network of the inflammation-related carcinogenesis, the potential molecular mechanism of TLR9 as well as the TLR9 based anti-tumor target therapy has been the hotspot in tumor research.

Key words: Toll like receptor, Toll like ligand, expression, head and neck squamous cell carcinoma

CLC Number: 

  • Q51

TrendMD: 
[1] Takeda K, Akira S. Toll-like receptors in innate immunity[J]. Int Immunol, 2005, 17(1):1-14.
[2] Dunne A, O’Neill LA. Adaptor usage and Toll-like receptor signaling specificity[J]. FEBS Lett, 2005, 579(15):3330-3335.
[3] Kelly JA, Moser KL, Harley JB. The genetics of systemic lupus erythematosus: putting the pieces to-gether[J]. Genes Immun, 2002, 3(Suppl 1):S71-S85.
[4] Hemmi H, Kaisho T, Takeda K, et al. The roles of Toll-like receptor 9, MyD88, and DNA-dependent protein kinase catalytic subunit in the effects of two distinct CpG DNAs on dendritic cell subsets[J]. J Immunol, 2003, 170(6):3059-3064.
[5] Ishii KJ, Akira S. Innate immune recognition of, and regulation by, DNA[J]. Trends Immunol, 2006, 27 (11):525-532.
[6] Suwarti S, Yamazaki T, Svetlana C, et al. Recogni-tion of CpG oligodeoxynucleotides by human Toll-like receptor 9 and subsequent cytokine induction[J]. Biochem Biophys Res Commun, 2013, 430(4):1234- 1239.
[7] Lee JW, Choi JJ, Seo ES, et al. Increased Toll-like receptor 9 expression in cervical neoplasia[J]. Mol Carcinog, 2007, 46(11):941-947.
[8] Kotrashetti VS, Nayak R, Bhat K, et al. Immunohis-tochemical expression of TLR4 and TLR9 in various grades of oral epithelial dysplasia and squamous cell carcinoma, and their roles in tumor progression: a pilot study[J]. Biotech Histochem, 2013, 88(6):311- 322.
[9] Min R, Zun Z, Siyi L, et al. Increased expression of Toll-like receptor-9 has close relation with tumour cell proliferation in oral squamous cell carcinoma[J]. Arch Oral Biol, 2011, 56(9):877-884.
[10] Ali A, Natah S, Konttinen Y. Differential expression of Toll-like receptors in chronic hyperplastic candi-dosis[J]. Oral Microbiol Immunol, 2008, 23(4):299- 307.
[11] Zhang Y, Wang Q, Ma A, et al. Functional expre-ssion of TLR9 in esophageal cancer[J]. Oncol Rep, 2014, 31(5):2298-2304.
[12] Takala H, Kauppila JH, Soini Y, et al. Toll-like recep-tor 9 is a novel biomarker for esophageal squamous cell dysplasia and squamous cell carcinoma progre-ssion[J]. J Innate Immun, 2011, 3(6):631-638.
[13] Dai Q, Li XP, Chai L, et al. Polymorphisms of Toll-like receptor 9 are associated with nasopharyngeal carcinoma susceptibility[J]. Tumour Biol, 2014, 35(4):3247-3253.
[14] Merrell MA, Ilvesaro JM, Lehtonen N, et al. Toll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activity[J]. Mol Cancer Res, 2006, 4(7):437-447.
[15] Kauppila JH, Karttunen TJ, Saarnio J, et al. Short DNA sequences and bacterial DNA induce esophageal, gastric, and colorectal cancer cell invasion[J]. APMIS, 2013, 121(6):511-522.
[16] Hemmi H, Takeuchi O, Kawai T, et al. A Toll-like receptor recognizes bacterial DNA[J]. Nature, 2000, 408(6813):740-745.
[17] Sheyhidin I, Nabi G, Hasim A, et al. Overexpression of TLR3, TLR4, TLR7 and TLR9 in esophageal squamous cell carcinoma[J]. World J Gastroenterol, 2011, 17(32):3745-3751.
[18] Ruan M, Zhang Z, Li S, et al. Activation of Toll-like receptor-9 promotes cellular migration via up-regulating MMP-2 expression in oral squamous cell carcinoma[J]. PLoS One, 2014, 9(3):e92748.
[19] Wang C, Cao S, Yan Y, et al. TLR9 expression in glioma tissues correlated to glioma progression and the prognosis of GBM patients[J]. BMC Cancer, 2010, 10:415.
[20] Väisänen MR, Väisänen T, Jukkola-Vuorinen A, et al. Expression of toll-like receptor-9 is increased in poorly differentiated prostate tumors[J]. Prostate, 2010, 70(8):817-824.
[21] Tuomela J, Sandholm J, Karihtala P, et al. Low TLR9 expression defines an aggressive subtype of triple-negative breast cancer[J]. Breast Cancer Res Treat, 2012, 135(2):481-493.
[22] Ronkainen H, Hirvikoski P, Kauppila S, et al. Absent Toll-like receptor-9 expression predicts poor prog-nosis in renal cell carcinoma[J]. J Exp Clin Cancer Res, 2011, 30:84.
[23] Kauppila JH, Takala H, Selander KS, et al. Increased Toll-like receptor 9 expression indicates adverse prognosis in oesophageal adenocarcinoma[J]. Histo-pathology, 2011, 59(4):643-649.
[24] Min R, Siyi L, Wenjun Y, et al. Toll-like receptor-9 agonists increase cyclin D1 expression partly through activation of activator protein-1 in human oral squa-mous cell carcinoma cells[J]. Cancer Sci, 2012, 103 (11):1938-1945.
[25] Schwartz C, Willebrand R, Huber S, et al. Eosinophil-specific deletion of IκBα in mice reveals a critical role of NF-κB-induced Bcl-xL for inhibition of apo-ptosis[J]. Blood, 2015, 125(25):3896-3904.
[26] Belmont L, Rabbe N, Antoine M, et al. Expression of TLR9 in tumor-infiltrating mononuclear cells en-hances angiogenesis and is associated with a worse survival in lung cancer[J]. Int J Cancer, 2014, 134 (4):765-777.
[27] Di JM, Pang J, Sun QP, et al. Toll-like receptor 9 agonists up-regulates the expression of cyclooxyge-nase-2 via activation of NF-κB in prostate cancer cells[J]. Mol Biol Rep, 2010, 37(4):1849-1855.
[28] Ilvesaro JM, Merrell MA, Li L, et al. Toll-like receptor 9 mediates CpG oligonucleotide-induced cellular invasion[J]. Mol Cancer Res, 2008, 6(10): 1534-1543.
[29] Xue YW, Zhang QF, Zhu ZB, et al. Expression of cyclooxygenase-2 and clinicopathologic features in human gastric adenocarcinoma[J]. World J Gastroen-terol, 2003, 9(2):250-253.
[30] Ruan M, Thorn K, Liu S, et al. The secretion of IL-6 by CpG-ODN-treated cancer cells promotes T-cell immune responses partly through the TLR-9/AP-1 pathway in oral squamous cell carcinoma[J]. Int J Oncol, 2014, 44(6):2103-2110.
[31] Weeratna RD, Bourne LL, Sullivan SM, et al. Com-bination of a new TLR9 agonist immunomodulator (CpG 7909) and paclitaxel for treatment of metasta-tic Lewis Lung Carcinoma(LLC)[J]. J Trans Edu, 2004, 3(3):271-288.
[32] Manegold C, Gravenor D, Woytowitz D, et al. Ran-domized phase Ⅱ trial of a Toll-like receptor 9 ago-nist oligodeoxynucleotide, PF-3512676, in combina-tion with first-line taxane plus platinum chemo-the-rapy for advanced-stage non-small-cell lung cancer [J]. J Clin Oncol, 2008, 26(24):3979-3986.
[33] Hirsh V, Paz-Ares L, Boyer M, et al. Randomized phase Ⅲ trial of paclitaxel/carboplatin with or without PF-3512676(Toll-like receptor 9 agonist) as first-line treatment for advanced non-small-cell lung cancer[J]. J Clin Oncol, 2011, 29(19):2667-2674.
[34] Chang LS, Leng CH, Yeh YC, et al. Toll-like recep-tor 9 agonist enhances anti-tumor immunity and inhibits tumor-associated immunosuppressive cells numbers in a mouse cervical cancer model following recombinant lipoprotein therapy[J]. Mol Cancer, 2014, 13:60.
[35] Katsuda M, Iwahashi M, Matsuda K, et al. Peptide vaccine therapy with TLR-9 agonist for patients with esophageal squamous cell carcinoma[J]. Gan To Kagaku Ryoho, 2011, 38(12):1942-1944.
[36] Machiels JP, Kaminsky MC, Keller U, et al. Phase Ib trial of the Toll-like receptor 9 agonist IMO-2055 in combination with 5-fluorouracil, cisplatin, and cetuximab as first-line palliative treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck[J]. Invest New Drugs, 2013, 31(5):1207-1216.
[1] Liu Shiyi, Chen Zhong, Zhang Suxin. Progress in research into programmed death-1/programmed death-ligand 1 immunotherapy strategies in human papillomavirus-positive head and neck squamous cell carcinoma [J]. Int J Stomatol, 2024, 51(1): 21-27.
[2] Li Hongfang,Chen Zhong,Zhang Suxin.. Research progress on immune checkpoint inhibitor combined with radiotherapy in head and neck squamous cell carcinoma [J]. Int J Stomatol, 2022, 49(5): 614-620.
[3] Zhao Manzhu,Song Jinlin. Research progress on expression distribution and regulation mechanism of clock genes in tooth development [J]. Int J Stomatol, 2022, 49(4): 380-385.
[4] Hao Fu,Sun Rui. Research progress on second primary carcinoma of head and neck squamous cell carcinoma [J]. Int J Stomatol, 2019, 46(5): 585-592.
[5] Zhou Chen, Ling Junqi. Epigenetics in tooth development and its implication in tooth regeneration [J]. Inter J Stomatol, 2016, 43(3): 318-324.
[6] Liu Shuang, Li Shu. Effects of pattern recognition receptors and pathogen associated molecular patterns in defense of periodontal disease [J]. Inter J Stomatol, 2016, 43(2): 212-215.
[7] Xiao Li1, Lin Yuxiang2, Ge Song3.. Recombination and expression of fimbriae protein for Porphyromonas gingivalis [J]. Inter J Stomatol, 2015, 42(6): 655-658.
[8] Huang Yihua, Ling Junqi. . Role of Toll-like receptor 2 and Toll-like receptor 4 in osteoblastic differentiation [J]. Inter J Stomatol, 2015, 42(4): 492-495.
[9] Zeng Suyun, Wang Jianguang. Effect of phosphatase and tensin homolog gene deleted on chromosome 10 in oral squamous cell carcinoma [J]. Inter J Stomatol, 2015, 42(3): 334-338.
[10] Fang Juan, Song Jingjing, Ma Da, Wang Yanqiong, Zhou Fangjing, Wang Zhi. An example for the application of data-mining from Oncomine database in the research of head and neck squamous cell carcinoma [J]. Inter J Stomatol, 2014, 41(6): 647-651.
[11] Yang Jiegang, Chen Liangwen, Li Xiaoxu, Wang Yulan, Meng Liuyan. Wingless-type mice mammary tumor virus integration site family and cleft lip and palate [J]. Inter J Stomatol, 2014, 41(3): 296-299.
[12] Li Xinyi, Duan Dingyu, Xu Yi.. Bacterial genes and proteins expressed differentially in biofilm and planktonic conditions [J]. Inter J Stomatol, 2013, 40(5): 661-666.
[13] Wang Lin, Liu Min, Hao Yuqing, Liu Yaling.. Research progress on Streptococcus gordonii AtlS autolysis [J]. Inter J Stomatol, 2013, 40(5): 667-669.
[14] Gong Qimei, Ling Junqi.. Research progress on gene chip technology and its applications in dental pulp biology [J]. Inter J Stomatol, 2012, 39(5): 608-611.
[15] Tian Yuanyuan, Hu Tao.. VicRK two-component signal transduction system of Streptococcus mutans [J]. Inter J Stomatol, 2012, 39(1): 89-92.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
[1] . [J]. Foreign Med Sci: Stomatol, 1999, 26(06): .
[2] . [J]. Foreign Med Sci: Stomatol, 1999, 26(06): .
[3] . [J]. Foreign Med Sci: Stomatol, 1999, 26(05): .
[4] . [J]. Foreign Med Sci: Stomatol, 1999, 26(05): .
[5] . [J]. Foreign Med Sci: Stomatol, 1999, 26(05): .
[6] . [J]. Foreign Med Sci: Stomatol, 1999, 26(04): .
[7] . [J]. Foreign Med Sci: Stomatol, 1999, 26(04): .
[8] . [J]. Foreign Med Sci: Stomatol, 1999, 26(04): .
[9] . [J]. Foreign Med Sci: Stomatol, 1999, 26(04): .
[10] . [J]. Foreign Med Sci: Stomatol, 1999, 26(04): .